Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial
Authors:
- 8 August 2023
- journal article
- research article
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (9) , e523-e531
Abstract
No abstract availableKeywords
Funding Information
- University of Lille
This publication has 31 references indexed in Scilit:
- Reliability and Diagnostic Accuracy of Radiography for the Diagnosis of Calcium Pyrophosphate Deposition: Performance of the Novel Definitions Developed by an International Multidisciplinary Working GroupArthritis & Rheumatology, 2023
- Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item ReductionArthritis Care & Research, 2021
- Review: Unmet Needs and the Path Forward in Joint Disease Associated With Calcium Pyrophosphate Crystal DepositionArthritis & Rheumatology, 2018
- Effect of Steady-State Atorvastatin on the Pharmacokinetics of a Single Dose of Colchicine in Healthy Adults Under Fasted ConditionsClinical Drug Investigation, 2014
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2012
- Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitorsArthritis & Rheumatism, 2011
- High versus low dosing of oral colchicine for early acute gout flare: Twenty‐four–hour outcome of the first multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison colchicine studyArthritis & Rheumatism, 2010
- Gout and Pseudogout in Hospitalized PatientsArchives of internal medicine (1960), 1993
- Colchicine and pseudogoutArthritis & Rheumatism, 1980
- Intravenous colchicine in the treatment of acute pseudogoutArthritis & Rheumatism, 1980